| β-Blockade: Benefits Beyond Blood Pressure Reduction? | |
| | |
MedLine Citation:
|
PMID: 22277144 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Hypertension is a major cardiovascular (CV) risk factor, but several other common conditions, including chronic obstructive pulmonary disease (COPD), osteoporosis, and peripheral arterial disease (PAD), have been shown to independently increase the risk of CV events and death. The physiological basis for an increased CV risk in those conditions probably lies in the augmentations of oxidative stress, endothelial dysfunction, systemic inflammation, and arterial stiffness, which all are also hallmarks of hypertension. β-Blockers have been used for the treatment of hypertension for more than 40 years, but a number of meta-analyses have demonstrated that treatment with these agents may be associated with an increased risk of CV events and mortality. However, the majority of primary prevention β-blocker trials employed atenolol, an earlier-generation β(1) -selective blocker whose mechanism of action is based on a reduction of cardiac output. Available evidence suggests that vasodilatory β-blockers may be free of the deleterious effects of atenolol. The purpose of this review is to summarize pathophysiologic mechanisms thought to be responsible for the increased CV risk associated with COPD, osteoporosis, and PAD, and examine the possible benefits of vasodilatory β-blockade in those conditions. Our examination focused on nebivolol, a β(1) -selective agent with vasodilatory effects most likely mediated via β(3) activation. |
| | |
Authors:
|
John R Cockcroft; Michala E Pedersen |
Related Documents
:
|
11057784 - Hypertensive renovasculopathies and the rise of blood pressure with age in japan and usa. 20368244 - Short-term couplings of the cardiovascular system in pregnant women suffering from pre-... 7318364 - Blood pressure and plasma sodium and potassium. 7612094 - Hyperthyroidism and seizures during pregnancy. 2230854 - Auscultatory mean blood pressure. 9468174 - The first decade of continuous monitoring of jugular bulb oxyhemoglobinsaturation: mana... |
Publication Detail:
|
Type: Journal Article Date: 2011-11-11 |
Journal Detail:
|
Title: Journal of clinical hypertension (Greenwich, Conn.) Volume: 14 ISSN: 1751-7176 ISO Abbreviation: J Clin Hypertens (Greenwich) Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-01-26 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100888554 Medline TA: J Clin Hypertens (Greenwich) Country: United States |
Other Details:
|
Languages: eng Pagination: 112-20 Citation Subset: IM |
Copyright Information:
|
© 2011 Wiley Periodicals, Inc. |
Affiliation:
|
From the Department of Cardiology, University of Cardiff, University Hospital, Cardiff, UK; 1 and the Royal Brompton Hospital, London, UK2. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antiplatelet therapy for transient ischemic attack.
Next Document: The role of nutraceutical supplements in the treatment of dyslipidemia.